Tern to host online presentation and Q&A session for existing and prospective shareholders

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Tuesday 26 March 2024.

Presenting will be members of Tern’s management team and management from Tern’s portfolio companies Device Authority, FundamentalVR, Talking Medicines and Wyld Networks.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_I_dqVC98R6yl6pjCbr2P_w

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted prior to 3 p.m. GMT on 26 March 2024 to: [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Evidence-based personas put behaviour at the centre of customer intelligence

Evidence-based personas shift customer intelligence from what people might say to what they are likely to do.

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Search